Logo Prima Biomed


Welcome to the Newsroom

05 November 2015

PRIMA BIOMED WILL PRESENT AT THE ICI EUROPE MEETING IN GERMANY, NOVEMBER 16-18, 2015


ENGLISH


SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) today announced that Dr. Frédéric Triebel, Chief Scientific and Medical Officer, will be presenting at the forthcoming Immune Checkpoint Inhibitors Europe meeting (ICI Europe), to be held at Bad Homburg in Germany from 16 to 18 November.

ICI Europe, focused exclusively on checkpoint modulators, will see experts from a variety of established and emerging pharma companies discussing matters such as clinically relevant biomarkers and preclinical models in immune-oncology, as well as combination strategies for clinical development. Dr. Triebel’s presentation will take place during a segment looking at the discovery of novel immune checkpoint pathways and will discuss LAG-3 as a ‘next generation’ checkpoint. In his presentation Dr. Triebel will show some of the pre-clinical data generated for Prima’s lead compound, IMP321, a first-in-class Antigen Presenting Cell-Activator, as well as the Phase IIa data in metastatic breast cancer in conjunction with paclitaxel.

(...)